Press releases - Pharmanutra

18/12/2024 - 2025 CORPORATE EVENTS CALENDAR PUBLICATION
25/11/2024 - DISTRIBUTION AGREEMENT FOR SIDERAL® PRODUCTS SIGNED IN CANADA
18/11/2024 - FIRST SIGNIFICANT SALES RESULTS IN CHINA
11/11/2024 - PHARMANUTRA S.P.A.: THE BOD APPROVES THE INTERIM MANAGEMENT REPORT AS AT SEPTEMBER 30, 2024
04/11/2024 - PHARMANUTRA S.P.A. APPLIES ITS PROPRIETARY SUCROSOMIAL® TECHNOLOGY TO VITAMINS AND LAUNCHES NEW SIDEVIT® LINE
29/10/2024 - AGREEMENT WITH AN INTERNATIONAL ADVISOR IN ORDER TO DEFINE A DEVELOPMENT PLAN FOR PHARMANUTRA USA
02/10/2024 - ALLEGATO 3F - SETTEMBRE 2024
09/09/2024 - BOD APPROVED THE FIRST HALF FINANCIAL REPORT AS AT 30 JUNE 2024
03/09/2024 - ALLEGATO 3F – AGOSTO 2024
03/09/2024 - LAUNCH OF TWO SIDERAL® PRODUCTS IN GERMANY
01/08/2024 - ALLEGATO 3F – LUGLIO 2024
24/07/2024 - SIGNIFICANT SALES AND MARKET POSITIONING RESULTS IN THE ITALIAN NUTRACEUTICAL MARKET
08/07/2024 - ALLEGATO 3F GIUGNO 2024
05/07/2024 - EFFECTIVENESS OF THE MERGER BY INCORPORATION
22/06/2024 - INTERNAL DEALING COMMUNICATION
18/06/2024 - THE DISTRIBUTION OF IRON-BASED DIETARY SUPPLEMENTS KICKS OFF IN MEXICO
13/06/2024 - A NEW STUDY HIGHLIGHTS THE EFFICACY, SUPERIORITY AND IMPROVED TOLERABILITY OF SIDERAL® COMPARED TO CONVENTIONAL IRON SUPPLEMENT TREATMENTS
12/06/2024 - INITIATION OF SHARE BUY-BACK PROGRAM
29/05/2024 - ASSUNZIONE QUALIFICA DI PMI
13/05/2024 - PHARMANUTRA S.P.A. THE BOD APPROVES THE INTERIM MANAGEMENT REPORT AS AT 31 MARCH2024 AND THE 2023 SUSTAINABILITY REPORT
15/04/2024 - THE MERGER BY INCORPORATION INTO PHARMANUTRA S.P.A. OF JUNIA PHARMA S.R.L. AND ALESCO S.R.L. HAS BEEN APPROVED
15/03/2024 - PHARMANUTRA S.P.A.: THE BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 DECEMBER 2023
26/02/2024 - APPROVAL OF THE MERGER PLAN
11/01/2024 - EURO 100 MILLION IN REVENUE REACHED IN THE YEAR OF ITS 20TH ANNIVERSARY SINCE ESTABLISHMENT
08/01/2024 - LOSS OF SME STATUS
21/12/2023 - PUBLICATION OF THE 2024 CORPORATE EVENTS CALENDAR
08/11/2023 - MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUER’S SECURITIES
06/11/2023 - BOD APPROVES INTERIM MANAGEMENT REPORT AS AT 30/09/2023
10/10/2023 - PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM
03/10/2023 - PHARMANUTRA S.P.A.: FIRST SALES ON THE US MARKET
19/09/2023 - PHARMANUTRA S.P.A.: HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2023
12/09/2023 - POLICY FOR THE MANAGEMENT OF THE DIALOGUE WITH ALL SHAREHOLDERS OF PHARMANUTRA S.P.A.
11/09/2023 - PHARMANUTRA S.P.A.: THE BOD APPROVED THE FIRST HALF FINANCIAL REPORT AS AT 30 JUNE 2023
30/08/2023 - PHARMANUTRA S.P.A.: LIPOCET (CETILAR®) GETS THE GREEN LIGHT TO BE CLASSIFIED AS A 'NOVEL FOOD' ALSO IN THE UK
03/08/2023 - PHARMANUTRA S.P.A.: CETILAR® WITH MARCELL JACOBS HEADING FOR PARIS 2024
17/07/2023 - PHARMANUTRA S.P.A.: THE BOARD OF DIRECTORS APPROVES THE 2022 SUSTAINABILITY REPORT AND APPOINTS THE SUSTAINABILITY GOVERNANCE
11/07/2023 - PHARMANUTRA S.P.A.: CETILAR® IS RECONFIRMED AS MAIN SPONSOR OF THE PISA SPORTING CLUB FOR 2023-2024
26/05/2023 - PHARMANUTRA S.P.A.: CETILAR® SIDE BY SIDE WITH FERNANDO ALONSO
08/05/2023 - PHARMANUTRA S.P.A.: BOARD OF DIRECTORS APPROVES INTERIM REPORT TO 31 MARCH 2023
12/04/2023 - PHARMANUTRA SIGNS THREE NEW AGREEMENTS FOR THE FOREIGN DISTRIBUTION OF SIDERAL® PRODUCTS
17/03/2023 - PHARMANUTRA S.P.A: DEPOSITO DOCUMENTAZIONE PER ASSEMBLEA DEGLI AZIONISTI
16/03/2023 - PHARMANUTRA: THE BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 DECEMBER 2022
21/02/2023 - PHARMANUTRA THE STRATEGIC GUIDELINES FOR THE NEXT YEARS WERE PRESENTED AT THE INVESTOR'S DAY
08/02/2023 - PHARMANUTRA PARTNERS WITH FERRARI TO FACE THE CHALLENGES OF THE NEW LE MANS HYPERCAR 499P
24/01/2023 - INTEGRATION OF THE 2023 CORPORATE EVENTS CALENDAR
12/01/2023 - PUBLICATION OF THE 2023 CORPORATE EVENTS CALENDAR
04/01/2023 - NEW DISTRIBUTION AGREEMENTS IN INDONESIA, KUWAIT AND MEXICO
12/12/2022 - NEW COMPANY PHARMANUTRA U.S.A. CORP. ESTABLISHED FOR DISTRIBUTION IN THE UNITED STATES
05/12/2022 - PHARMANUTRA S.P.A. COMPLETES AKERN S.R.L. ACQUISITION
15/11/2022 - PHARMANUTRA PARTNERS WITH THE LUNA ROSSA PRADA PIRELLI TEAM FOR THE 37TH EDITION OF THE AMERICA’S CUP
07/11/2022 - BOARD OF DIRECTORS APPROVES INTERIM MANAGEMENT REPORT AS AT 30 SEPTEMBER 2022
15/09/2022 - PHARMANUTRA S.P.A. LAUNCHES NEW PRODUCTS CETILAR® ORO AND APPORTAL® VITAL
14/09/2022 - HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2022
05/09/2022 - THE BOD APPROVES THE FIRST HALF FINANCIAL REPORT AS AT 30/06/2022 AND THE GROUP’S FIRST SUSTAINABILITY REPORT
04/08/2022 - BUY-BACK REPORT JULY 2022
26/07/2022 - PHARMANUTRA S.P.A.: FIRST ACQUISITION CLOSING OF AKERN S.R.L. FINALISED
06/07/2022 - BUY-BACK REPORT JUNE 2022
17/06/2022 - GOLDEN POWER NOTIFICATION FILED IN CONNECTION WITH THE ACQUISITION OF 100% OF AKERN S.R.L.
15/06/2022 - SIGNING OF THE AGREEMENT FOR THE ACQUISITION OF 100% OF AKERN S.R.L.
08/06/2022 - BUY-BACK REPORT MAY 2022
27/05/2022 - PUBLICATION OF THE SHAREHOLDERS’ MEETINGS MINUTES HELD ON 27/04/2022
16/05/2022 - PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM
12/05/2022 - INTERIM FINANCIAL REPORT AS OF 31 MARCH 2022 NOW AVAILABLE
09/05/2022 - PHARMANUTRA S.P.A.: INTERIM REPORT AS AT 31 MARCH 2022
02/05/2022 - SYNTHETIC REPORT ON VOTING RESULTS OF THE SHAREHOLDERS’ MEETINGS 27/04/2022
27/04/2022 - RESOLUTIONS OF THE SHAREHOLDERS' MEETING OF 27/04/2022
11/04/2022 - BUY-BACK REPORT MARCH 2022
31/03/2022 - NOTICE OF PUBLICATIONOF THE 2021 ANNUAL FINANCIAL REPORT
18/03/2022 - PHARMANUTRA S.P.A.: FILING OF DOCUMENTS FOR THE SHAREHOLDERS’ MEETING
18/03/2022 - PHARMANUTRA S.P.A.: THE BOARD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 DECEMBER 2021
08/03/2022 - BUY-BACK REPORT FEBRUARY 2022
23/02/2022 - MODIFICATION OF THE 2022 CORPORATE EVENTS CALENDAR
14/02/2022 - THE EUROPEAN UNION AUTHORISES MARKETING OF CFAS AS A NOVEL FOOD
07/02/2022 - BUY-BACK REPORT JANUARY 2022
31/01/2022 - PHARMANUTRA S.P.A. CONFIRMS STRONG SALES INCREASE
24/01/2022 - PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM
17/01/2022 - PHARMANUTRA S.P.A.: NEW LICENCE GRANTED IN THE U.S.A.
14/01/2022 - PUBLICATION OF THE 2022 CORPORATE EVENTS CALENDAR
13/01/2022 - PHARMANUTRA S.P.A. STRENGTHENS PRESENCE ON TAIWANESE MARKET
02/12/2021 - PHARMANUTRA S.P.A. JOINS THE “MSCI WORLD SMALL CAP” AND “FTSE ITALIA MID CAP” INDICES
25/11/2021 - PHARMANUTRA GROUP: THREE NEW PATENTS RELEASED
16/11/2021 - NEW INTERNATIONAL AGREEMENT FOR THE DISTRIBUTION OF SIDERAL® IN ARGENTINA
12/11/2021 - INTERIM FINANCIAL REPORT AS OF 30 SEPTEMBER 2021
08/11/2021 - BOARD OF DIRECTORS APPROVES INTERIM MANAGEMENT REPORT AS AT 30 SEPTEMBER 2021
25/10/2021 - PHARMANUTRA S.P.A.: ALESCO SUBSIDIARY OBTAINS PATENT FOR THE NEW SUCROSOMIAL® BERBERINE
21/10/2021 - PHARMANUTRA S.P.A. OBTAINS THE GRANT OF CETILAR® PROCESS PATENT IN INDIA
13/10/2021 - NEW DISTRIBUTION AGREEMENTS WITH AMERICAN TAIWAN BIOPHARM CO. AND ARGON DRUG STORE
04/10/2021 - PHARMANUTRA S.P.A. CONFIRMS GROWTH TREND IN ITALY AND STRONG RECOVERY ON INTERNATIONAL MARKETS
13/09/2021 - HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2021
06/09/2021 - BOD APPROVED THE FIRST HALF FINANCIAL REPORT AS AT 30 JUNE 2021
25/08/2021 - PHARMANUTRA S.P.A. OBTAINS THE GRANT OF CETILAR® PATENT IN CHINA
21/07/2021 - EFSA IN FAVOUR OF AUTHORISING LIPOCET (CETILAR®) AS A NOVEL FOOD
29/06/2021 - BOD APPROVES THE NEW PROCEDURE RELATING TO TRANSACTIONS WITH RELATED PARTIES
10/06/2021 - AGREEMENT FOR THE DISTRIBUTION OF SIDERAL® IN GERMANY SIGNED WITH FRESENIUS KABI
07/06/2021 - SALES FIGURES FOR MAY 2021: OVER 300,000 UNITS PER MONTH SOLD
26/05/2021 - PUBLICATION OF SHAREHOLDERS’ MEETINGS MINUTES 26/04/2021
10/05/2021 - PHARMANUTRA S.P.A.: BOARD APPROVES INTERIM MANAGEMENT REPORT AS OF 31ˢᵗ MARCH 2021
03/05/2021 - PHARMANUTRA S.P.A.: ITALIAN MARKET DOUBLE FIGURE GROWTH ONCE AGAIN
29/04/2021 - SYNTHETIC REPORT ON VOTING RESULTS OF THE ORDINARY SHAREHOLDERS’ MEETINGS HELD ON APRIL 26TH 2021
26/04/2021 - PHARMANUTRA S.P.A.: ORDINARY SHAREHOLDERS’ MEETING OF 26ᵗʰ APRIL 2021
19/04/2021 - PHARMANUTRA S.P.A. LAUNCHES ITS NEW SIDERAL® MED
07/04/2021 - A NEW STUDY DEMONSTRATES THE EFFECTS OF USING APPORTAL® IN PATIENTS SUFFERING FROM CHRONIC COVID SYNDROME
01/04/2021 - FILING OF THE REPORT ON THE REMUNERATION POLICY
31/03/2021 - NEW FILING OF DOCUMENTS FOR THE SHAREHOLDERS’ MEETING
25/03/2021 - FILING OF DOCUMENTS FOR THE SHAREHOLDERS’ MEETING
22/03/2021 - PHARMANUTRA SPA: BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AS AT 31ST DECEMBER 2020
08/03/2021 - MODIFICATION OF THE 2021 CORPORATE EVENTS CALENDAR
29/01/2021 - PUBLICATION OF THE 2021 CORPORATE EVENTS CALENDAR
18/01/2021 - PHARMANUTRA S.P.A. APPOINTS A SUPERVISORY BODY
22/12/2020 - CETILAR® PATCH AND CETILAR® TAPE CERTIFIED CLASS 2A MEDICAL DEVICES
11/12/2020 - BORSA ITALIANA ORDERS ADMISSION OF THE ORDINARY SHARES OF PHARMANUTRA TO TRADING ON THE MTA - STAR SEGMENT
11/12/2020 - THE INFORMATION PROSPECTUS ON ADMISSION TO TRADING ON THE MTA - STAR SEGMENT HAS BEEN PUBLISHED
11/12/2020 - CONSOB APPROVES THE INFORMATION PROSPECTUS FOR ADMISSION TO TRADING ON MTA - STAR SEGMENT
04/12/2020 - BORSA ITALIANA DISPONE L’AMMISSIONE A QUOTAZIONE SUL MERCATO MTA DELLE AZIONI ORDINARIE DI PHARMANUTRA S.P.A.
01/12/2020 - PHARMANUTRA S.P.A.: NEW DISTRIBUTION AGREEMENT FOR BRAZIL
18/11/2020 - PHARMANUTRA S.P.A.: NEW INTERNATIONAL DISTRIBUTION AGREEMENTS
11/11/2020 - PHARMANUTRA S.P.A.: REGISTRATION OF THE BRANDS CETILAR® AND SIDERAL® GRANTED IN THE USA
09/11/2020 - PHARMANUTRA S.P.A.: CONSOLIDATED FINANCIAL REPORT AS AT 30TH SEPTEMBER 2020
06/11/2020 - PHARMANUTRA S.P.A.: AGGIORNAMENTO CALENDARIO EVENTI SOCIETARI 2020
03/11/2020 - PHARMANUTRA S.P.A. PRESENTS A NEW CETILAR® LINE PRODUCT
27/10/2020 - MTA STAR LISTING PROCESS: AMENDMENT TO THE EXISTING SHAREHOLDERS’ AGREEMENT AND COMMITMENT TO THE 36 MONTHS LOCK UP
23/10/2020 - THE MTA STAR LISTING PROCESS: BOD OF PHARMANUTRA S.P.A.
13/10/2020 - ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING AND BOARD OF DIRECTORS’ MEETING DOWNSTREAM OF THE SHAREHOLDERS’ MEETING
25/09/2020 - COOPTAZIONE DI DUE CONSIGLIERI DI AMMINISTRAZIONE INDIPENDENTI E CONVOCAZIONE DELL’ASSEMBLEA DEGLI AZIONISTI
25/09/2020 - COMUNICAZIONE AI SENSI DELL’ART. 17 DEL REGOLAMENTO EMITTENTI AIM ITALIA
24/09/2020 - INCREMENTO DEL FLOTTANTE AI FINI DELLA QUOTAZIONE SUL SEGMENTO STAR DEL MTA ATTRAVERSO CESSIONI DI PARTECIPAZIONI DEI SOCI DI RIFERIMENTO
21/09/2020 - LAUNCH OF THE MTA STAR SEGMENT LISTING APPROVED BY THE BOARD OF DIRECTORS
14/09/2020 - EXCEPTIONAL RESULTS IN THE FIRST HALF OF 2020. DOUBLE DIGIT GROWTH.
10/09/2020 - PHARMANUTRA S.P.A.: NEW DISTRIBUTION AGREEMENT SIGNED FOR BOLIVIA
08/09/2020 - NEW DISTRIBUTION AGREEMENT SIGNED BETWEEN ALESCO AND DELTAGEN UK – ATURA
27/08/2020 - THE GROUP KEEPS ON GROWING UNLIKE THE ITALIAN MARKET
20/07/2020 - PHARMANUTRA CELEBRATES THREE YEARS SINCE BEING LISTED ON THE AIM ITALIA MARKET
14/07/2020 - PHARMANUTRA S.P.A.: REVENUE INCREASES +17% IN THE FIRST HALF OF 2020
17/06/2020 - PHARMANUTRA S.P.A.: COMUNICAZIONE AI SENSI DELL’ART. 17 DEL REGOLAMENTO EMITTENTI AIM ITALIA
12/06/2020 - AGREEMENT RELATED TO THE PATENT BOX REGIME SIGNED WITH THE REVENUE OFFICE
25/05/2020 - PHARMANUTRA S.P.A. TAKES PART IN THE AIM ITALIA CONFERENCE 2020
07/05/2020 - CETILAR® OBTAINS PLAY SURE DOPING FREE CERTIFICATION
29/04/2020 - PHARMANUTRA S.P.A.:NEW DISTRIBUTION AGREEMENTS IN EUROPE, ASIA AND LATIN AMERICA.
27/04/2020 - PHARMANUTRA S.P.A.: ORDINARY SHAREHOLDERS’ MEETING OF 27TH APRIL 2020
16/04/2020 - PRESENTATION OF PROPOSALS FOR APPOINTMENTS TO THE BOARD OF DIRECTORS OF PHARMANUTRA S.P.A.
15/04/2020 - PHARMANUTRA S.P.A.: PFIZER INVESTS IN SUCROSOMIAL® TECHNOLOGY
09/04/2020 - PHARMANUTRA S.P.A.: NOTICE OF CALL FOR ORDINARY SHAREHOLDERS’ MEETING
06/04/2020 - PHARMANUTRA S.P.A.: PROPOSAL TO AUTHORISE THE PURCHASE AND DISPOSAL OF TREASURY STOCK
03/04/2020 - PHARMANUTRA S.P.A.: FIGURES FOR THE FIRST QUARTER 2020 GROWING
25/03/2020 - PHARMANUTRA S.P.A. OBTAINS APPROVAL FOR TWO NEW PATENTS IN INDIA AND UNITED STATES
23/03/2020 - PHARMANUTRA S.P.A.: DOUBLE FIGURE GROWTH CONTINUES
23/03/2020 - PHARMANUTRA S.P.A.: COMUNICAZIONE AI SOCI IN MERITO AL DECRETO LEGGE “CURA ITALIA” EMANATO DAL GOVERNO
10/03/2020 - PHARMANUTRA S.P.A SUPPORTING THE NATIONAL HEALTH SERVICE IN THIS EMERGENCY
05/03/2020 - PHARMANUTRA S.P.A. LANCIA LA NUOVA CAMPAGNA MULTICANALE “FATTI TROVARE PRONTO” DEDICATA AD APPORTAL®.
07/02/2020 - NEW AGREEMENTS FOR THE DISTRIBUTION OF SIDERAL® IN MEXICO, THE CZECH REPUBLIC AND SLOVAKIA
03/02/2020 - PHARMANUTRA S.P.A.: CORPORATE EVENTS CALENDAR 2020
16/01/2020 - PHARMANUTRA S.P.A. PRESENTE ALLA SECONDA EDIZIONE DELL’“ITALIAN MID CAP CONFERENCE” DI MEDIOBANCA.
08/01/2020 - PHARMANUTRA S.P.A. ENGAGES MEDIOBANCA S.P.A. AS SPECIALIST
08/01/2020 - FOOD SUPPLEMENT MARKET IS GROWING IN ITALY AND SIDERAL® FORTE 20 CAPSULES IS THE MOST SOLD NUTRITIONAL SUPPLEMENT IN THE COUNTRY.
19/12/2019 - MEDIOBANCA – BANCA DI CREDITO FINANZIARIO S.P.A. STARTS SHARE COVERAGE
28/11/2019 - ONGOING INTERNATIONAL EXPANSION FOR THE GROUP, STRENGTHENED BY NEW PATENTS APPROVED
19/11/2019 - JUNIA PHARMA SRL LAUNCHES BLEFARENE BABY ON THE MARKET
12/11/2019 - PHARMANUTRA S.P.A. OBTAINS PATENT FOR A NEW COMPOSITION USED FOR TREATING CARDIOVASCULAR DISEASES
08/11/2019 - PHARMANUTRA WAS EXHIBITING AT CPHI WORLDWIDE 2019 IN FRANKFURT
05/11/2019 - PHARMANUTRA OBTAINS THE SOLID IRON PATENT FOR THE USA
22/10/2019 - PHARMANUTRA AT THE AIM ITALIA CONFERENCE DRIVEN BY THE POSITIVE ANALYST FORECASTS
17/09/2019 - PHARMANUTRA S.P.A.: RESULTS OF THE FIRST SEMESTER CONFIRM GROWTH IN DOUBLE FIGURES
10/09/2019 - PHARMANUTRA S.P.A. NEW AGREEMENT SIGNED WITH WERT PHILIPPINES FOR THE SIDERAL® RANGE
28/08/2019 - NEW AGREEMENT FOR THE DISTRIBUTION OF THE SIDERAL LINE IN TAIWAN
02/08/2019 - HISTORICAL MONTH-BASED SALES RECORD IN ITALY
29/07/2019 - ANTICIPATED INFORMATION ON THE PRELIMINARY CONSOLIDATED REVENUES OF THE FIRST HALF OF 2019
16/07/2019 - PHARMANUTRA S.P.A., RESULTS COME FROM RESEARCH
05/07/2019 - CETILAR® ONCE AGAIN THE MAIN SPONSOR OF PARMA CALCIO FOR THE 2019/2020 SEASON
12/06/2019 - PHARMANUTRA: SALES NETWORK EVOLUTION AND NEW COMMERCIAL STRATEGIES
05/06/2019 - THE INTERNATIONAL EXPANSION OF THE SIDERAL® LINE CONTINUES
29/05/2019 - NOTIFICATION PURSUANT TO ARTICLE 17 OF THE AIM ITALIA ISSUERS REGULATIONS
27/05/2019 - PHARMANUTRA PRESENTE ALL’AIM ITALIA CONFERENCE
10/05/2019 - CO-OPTATION OF A NEW ADMINISTRATOR
06/05/2019 - NEW INTERNATIONAL AGREEMENTS FOR THE CETILAR® LINE
23/04/2019 - JORDAN JOINS THE PHARMANUTRA PARTNER COUNTRIES
16/04/2019 - NOTIFICATION PURSUANT TO ARTICLE 17 OF THE AIM ITALIA ISSUERS REGULATIONS
16/04/2019 - NEW TRANSACTION BETWEEN SHAREHOLDERS
16/04/2019 - RESIGNATION OF A BOARD MEMBER
16/04/2019 - CLARIFICATION REGARDING THE 2018 DIVIDEND
16/04/2019 - SHAREHOLDERS' MEETING OF 15.04.2019
18/03/2019 - NEW INTERNATIONAL AGREEMENTS FOR THE DISTRIBUTION OF CETILAR® AND ULTRAMAG®
13/03/2019 - PHARMANUTRA DRAFT FINANCIAL STATEMENTS AND CONSOLIDATED FINANCIAL STATEMENTS AT 31.12.2018
12/03/2019 - THE 7TH EDITION OF THE INTERNATIONAL MULTIDISCIPLINARY COURSE ON IRON DEFICIENCY IN ROME
21/02/2019 - PHARMANUTRA SIGNS TWO NEW AGREEMENTS FOR THE DISTRIBUTION OF SUCROSOMIAL IRON IN GREECE AND UKRAINE
15/01/2019 - PHARMANUTRA SIGNS AN AGREEMENT WITH TRIGEN PHARMA INTERNATIONAL FOR THE DISTRIBUTION OF SIDERAL® PRODUCTS IN PAKISTAN
10/01/2019 - PHARMANUTRA: CORPORATE EVENTS CALENDAR 2019
20/12/2018 - PHARMANUTRA SIGNS AN IMPORTANT AGREEMENT TO DISTRIBUTE THE CETILAR® LINE IN THAILAND, OPENING UP THE SOUTH EAST ASIAN MARKET
14/12/2018 - AIM ITALY: PHARMANUTRA IN THE TOP 10 FOR PERFORMANCE AND CAPITALISATION
10/12/2018 - NEW AREAS OF APPLICATION RECOGNISED FOR SUCROSOMIAL IRON
04/12/2018 - PHARMANUTRA JOINS FARMINDUSTRIA
21/11/2018 - THE GROWTH TREND CONTINUES IN THE FIRST 9 MONTHS OF 2018: SALES ABROAD EXCEED SALES IN ITALY
05/11/2018 - FURTHER ACKNOWLEDGMENTS FOR SUCROSOMIAL IRON®
08/10/2018 - NEW RECOGNITIONS TO SUCROSOMIAL IRON®
04/10/2018 - NOTICE PURSUANT TO ARTICLE 17 OF AIM ITALIA ISSUER REGULATION
01/10/2018 - AN AGREEMENT HAS BEEN SIGNED WITH FRESENIUS KABI FOR THE DISTRIBUTION OF SUCROSOMIAL® IRON BASED PRODUCTS IN SWITZERLAND
26/09/2018 - PHARMANUTRA S.P.A.: THE RESULTS OF THE FIRST HALF CONFIRM A DOUBLE-DIGIT GROWTH
13/09/2018 - PHARMANUTRA GROUP LAUNCHES FOUR NEW PRODUCTS
30/08/2018 - PHARMANUTRA GROUP IS STILL GROWING ON THE ITALIAN MARKET
08/08/2018 - PHARMANUTRA CONFERMA LA TITLE SPONSORSHIP CON IL PARMA CALCIO 1913
26/07/2018 - PHARMANUTRA: REVENUES FOR THE FIRST HALF OF 2018 UP BY 20%. THE GROUP STRENGTHENS ITS INTERNATIONAL PRESENCE
18/07/2018 - PHARMANUTRA: GROWTH IN BUSINESS AND VALUE ONE YEAR FROM LISTING ON THE STOCK EXCHANGE
11/07/2018 - ULTRAMAG: SUCROSOMIAL TECHNOLOGY REVOLUTIONISES THE MAGNESIUM MARKET
05/07/2018 - PHARMANUTRA TAKES CENTRE STAGE AT THE “HEALTHCARE FORUM” AT THE BORSA ITALIANA
04/07/2018 - PHARMANUTRA PARTICIPATES IN THE "HEALTH CARE FORUM" IN BORSA ITALIANA
03/07/2018 - PHARMANUTRA: FRANCESCO SARTI APPOINTED CHIEF FINANCIAL OFFICER OF THE GROUP
28/06/2018 - PHARMANUTRA: NEW SALES RECORD IN MAY
28/05/2018 - NEW COMMERCIAL AGREEMENTS SIGNED FOR THE DISTRIBUTION OF SUCROSOMIAL® IRON ABROAD
23/04/2018 - PHARMANUTRA: SHAREHOLDERS' MEETING OF 23 APRIL 2018
11/04/2018 - 6TH INTERNATIONAL MULTIDISCIPLINARY COURSE ON IRON DEFICIENCY (IMCID)
06/04/2018 - PHARMANUTRA OBTAINS A PATENT FOR CETILAR® RM
27/03/2018 - PHARMANUTRA: SUCROSOMIAL® IRON CHOSEN AS PRODUCT OF THE YEAR BY ISRAELI CONSUMERS
20/03/2018 - PHARMANUTRA: THE BOARD OF DIRECTORS APPROVES THE DRAFT SEPARATE AND CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED 31 DECEMBER 2017
02/03/2018 - PHARMANUTRA: HIGHLY SUCCESSFUL FIRST EDITION OF THE CONVENTION DEDICATED TO INTERNATIONAL PARTNERS
22/02/2018 - PHARMANUTRA: 2017 PRELIMINARY RESULTS DOUBLE-DIGIT REVENUE AND MARGIN GROWTH
01/02/2018 - PHARMANUTRA: IN ARRIVO 4 NUOVI PRODOTTI SUL MERCATO
27/01/2018 - CALENDARIO DEGLI EVENTI SOCIETARI
18/10/2017 - COMMUNICATION OF CHANGING SOCIAL CAPITAL
30/09/2017 - COMUNICATO STAMPA - CONVERSIONE DELLE PRICE ADJUSTMENT SHARE
30/09/2017 - ESERCIZIO DEI WARRANT DI PHARMANUTRA S.P.A. PER IL PERIODO DAL 1 AL 29 SETTEMBRE 2017
18/09/2017 - PHARMANUTRA S.P.A. APPROVA LA RELAZIONE SEMESTRALE AL 30 GIUGNO 2017
11/09/2017 - PHARMANUTRA: CETILAR® DIVENTA MAIN SPONSOR DEL PARMA CALCIO 1913
31/08/2017 - ESERCIZIO DEI WARRANT DI PHARMANUTRA S.P.A. PER IL PERIODO DAL 1 AL 31 AGOSTO 2017
01/08/2017 - VERIFICATA LA CONDIZIONE DI ACCELERAZIONE DEI WARRANT PHARMANUTRA S.P.A.
01/08/2017 - COMUNICAZIONE DI ACCELERAZIONE WARRANT PHARMANUTRA S.P.A. IT0005274185
27/07/2017 - CALENDARIO DEGLI EVENTI SOCIETARI 2017
24/07/2017 - COMUNICAZIONE AI SENSI DELL’ART. 17 DEL REGOLAMENTO EMITTENTI AIM ITALIA
18/07/2017 - PRIMO GIORNO DI NEGOZIAZIONE DELLE AZIONI ORDINARIE E DEI WARRANT DI PHARMANUTRA S.P.A. SULL’AIM ITALIA
14/07/2017 - AMMISSIONE ALLE NEGOZIAZIONI DELLE AZIONI ORDINARIE E DEI WARRANT DI PHARMANUTRA S.P.A. SUL MERCATO AIM ITALIA